Brad Martin v. Actavis Inc., No. 22-2675 (7th Cir. 2023)Annotate this Case
Plaintiff was taking a testosterone replacement therapy drug (“TRT”) called Androderm when he suffered a heart attack. The resulting lawsuits against TRT-producing pharmaceutical companies were consolidated as multidistrict litigation (“MDL”), and Plaintiff filed his lawsuit as part of that MDL. When Defendant Actavis, the company that produces Androderm, reached a global settlement with most of the MDL plaintiffs, Plaintiff opted to take his case to trial. Plaintiff’s attorney filed a motion for a new trial, alleging that Actavis had intentionally withheld evidence to protect its defense strategy against Plaintiff. Plaintiff’s attorney received the last documents in a months-overdue discovery production for another Androderm case in the MDL on which he was also lead counsel. These documents included a previously undisclosed letter from the Food and Drug Administration (“FDA”) requiring Actavis to conduct a trial to study a potential causal link between Androderm and high blood pressure. The district court denied the motion, holding that the evidence did not warrant a new trial.
The Seventh Circuit affirmed, holding that the FDA letter would probably not have resulted in a verdict in Plaintiff’s favor. The court explained that even if the high blood pressure evidence had been more important to the trial, the considerations highlighted in Marcus make clear that the FDA study would not have made a new outcome probable. Removing Actavis’s blood pressure argument would leave seven alternative causes for Plaintiff’s heart attack. And the significance of Plaintiff’s blood pressure had already been undercut throughout trial. Taken together, the introduction of the FDA letter simply would not make a different outcome probable.